These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27656786)

  • 1. Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients.
    Voltzenlogel V; Ernst A; de Sèze J; Brassat D; Manning L; Berna F
    Conscious Cogn; 2016 Oct; 45():200-209. PubMed ID: 27656786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional study using self-defining memories to explore personal identity throughout adulthood.
    Fritsch A; Voltzenlogel V; Cuervo-Lombard C
    Dev Psychol; 2024 Feb; 60(2):363-375. PubMed ID: 38095997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Identity Motives on Quality of Life and Depressive Symptoms: A Comparison Between Young Adults With Multiple Sclerosis and Healthy Peers.
    Calandri E; Graziano F; Borghi M; Bonino S; Cattelino E
    Front Psychol; 2020; 11():589815. PubMed ID: 33304300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous hematopoietic cell transplantation in multiple sclerosis.
    Bell SM; Sharrack B; Snowden JA
    Expert Opin Biol Ther; 2017 Jan; 17(1):77-86. PubMed ID: 27657737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shared decision-making in multiple sclerosis.
    Colligan E; Metzler A; Tiryaki E
    Mult Scler; 2017 Feb; 23(2):185-190. PubMed ID: 27663871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The change in the sex ratio in multiple sclerosis is driven by birth cohort effects.
    Ajdacic-Gross V; Schmid M; Mutsch M; Steinemann N; von Wyl V; Bopp M
    Eur J Neurol; 2017 Jan; 24(1):98-104. PubMed ID: 27666339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis.
    Risson V; Ghodge B; Bonzani IC; Korn JR; Medin J; Saraykar T; Sengupta S; Saini D; Olson M
    J Med Internet Res; 2016 Sep; 18(9):e249. PubMed ID: 27658498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity.
    Schwenkenbecher P; Sarikidi A; Wurster U; Bronzlik P; Sühs KW; Raab P; Stangel M; Pul R; Skripuletz T
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27657060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    Merschhemke M; Tomic D; Putzki N
    JAMA Neurol; 2016 Nov; 73(11):1375. PubMed ID: 27669336
    [No Abstract]   [Full Text] [Related]  

  • 10. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
    Chew WS; Wang W; Herr DR
    Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort.
    Cohan S; Chen C; Baraban E; Stuchiner T; Grote L
    BMC Neurol; 2016 Sep; 16(1):184. PubMed ID: 27658385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply.
    Hatcher SE; Waubant E; Graves JS
    JAMA Neurol; 2016 Nov; 73(11):1376. PubMed ID: 27669526
    [No Abstract]   [Full Text] [Related]  

  • 13. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    Andrade C
    JAMA Neurol; 2016 Nov; 73(11):1375-1376. PubMed ID: 27669463
    [No Abstract]   [Full Text] [Related]  

  • 14. Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Bjørnevik K; Riise T; Bostrom I; Casetta I; Cortese M; Granieri E; Holmøy T; Kampman MT; Landtblom AM; Magalhaes S; Pugliatti M; Wolfson C; Myhr KM
    Mult Scler; 2017 Jun; 23(7):1018-1024. PubMed ID: 27663872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses.
    Fraussen J; Claes N; Van Wijmeersch B; van Horssen J; Stinissen P; Hupperts R; Somers V
    Clin Immunol; 2016 Dec; 173():124-132. PubMed ID: 27717695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive vs. non-adaptive cognitive training by means of a personalized App: a randomized trial in people with multiple sclerosis.
    Pedullà L; Brichetto G; Tacchino A; Vassallo C; Zaratin P; Battaglia MA; Bonzano L; Bove M
    J Neuroeng Rehabil; 2016 Oct; 13(1):88. PubMed ID: 27716336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
    Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
    BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An emerging role for eotaxins in neurodegenerative disease.
    Huber AK; Giles DA; Segal BM; Irani DN
    Clin Immunol; 2018 Apr; 189():29-33. PubMed ID: 27664933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.
    Kavanagh D; McGlasson S; Jury A; Williams J; Scolding N; Bellamy C; Gunther C; Ritchie D; Gale DP; Kanwar YS; Challis R; Buist H; Overell J; Weller B; Flossmann O; Blunden M; Meyer EP; Krucker T; Evans SJ; Campbell IL; Jackson AP; Chandran S; Hunt DP
    Blood; 2016 Dec; 128(24):2824-2833. PubMed ID: 27663672
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.